Particular Clinical Trial Challenges
rapid cross-over/drop-out
- eg. cessation (multi-drug to interruption)
- intent-to-treat becomes meaningless
- treatment-received becomes biased
availability of new treatments or strategies
- e.g. genotypic testing, compassionate access
- when not built into current protocol